Human physiologically based pharmacokinetic model for propofol

BMC Anesthesiology

Volumn 5, Issue , 2005, Pages

  Levitt, David G ^a   Schnider, Thomas W ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Institut fur Anasthesiologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PROPOFOL;

ADIPOSE TISSUE; ADULT; AGE; AGED; ARTICLE; BODY FAT; BOLUS INJECTION; CALCULATION; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG INFUSION; DRUG RELEASE; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; LIVER CLEARANCE; LUNG; MALE; MORBID OBESITY; PARTITION COEFFICIENT; PREDICTION; PROCESS MODEL; STATISTICAL ANALYSIS;

EID: 27644531073     PISSN: 14712253     EISSN: 14712253     Source Type: Journal    
DOI: 10.1186/1471-2253-5-4     Document Type: Article

References (51)

1. Weaver BM, Staddon GE, Mapleson WW: Tissue/blood and tissue/water partition coefficients for propofol in sheep. Br J Anaesth 2001, 86:693-703.
2. Steward A, Allott PR, Cowles At, Mapleson WW. Solubility coefficients for inhaled anaesthetics for water, oil and biological media. Br J Anaesth 1973, 45:282-293.
3. Levitt DG: PKQuest: capillary permeability limitation and plasma protein binding - application to human inulin, dicloxacillin and ceftriaxone pharmacokinetics. BMC Clin Pharmacol 2002, 2:7.
4. Levitt DG: PKQuest: volatile solutes - application to enflurane, nitrous oxide, halothane, methoxyflurane and toluene pharmacokinetics. BMC Anesthesiol 2002, 2:5.
5. Levitt DG: PKQuest: measurement of intestinal absorption and first pass metabolism - application to human ethanol pharmacokinetics. BMC Clin Pharmacol 2002, 2:4.
6. Levitt DG: PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol. BMC Clin Pharmacol 2002, 2:5.
7. Levitt DG: The use of a physiologically based pharmacokinetic model to evaluate deconvolution measurements of systemic absorption. BMC Clin Pharmacol 2003, 3:1.
8. Levitt DG: The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol 2003, 3:3.
9. Levitt DG: Physiologically based pharmacokinetic modeling of arterial - antecubital vein concentration difference. BMC Clin Pharmacol 2004, 4:2.
10. Gargas ML, Burgess RJ, Voisard DE, Cason GH, Andersen ME: Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. Toxicol Appl Pharmacol 1989, 98:87-99.
11. Poulin P, Theil FP: A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 2000, 89:16-35.
12. Yokogawa K, Ishizaki J, Ohkuma S, Miyamoto K: Influence of lipophilicity and lysosomal accumulation on tissue distribution kinetics of basic drugs: a physiologically based pharmacokinetic model. Methods Find Exp Clin Pharmacol 2002, 24:81-93.
13. Ishizaki J, Yokogawa K, Nakashima E, Ichimura F: Prediction of changes in the clinical pharmacokinetics of basic drugs on the basis of octanol-water partition coefficients. J Pharm Pharmacol 1997, 49:762-767.
14. de la Fuente L, Lukas JC, Vazquez JA, Jauregizar N, Calvo R, Suarez E: 'In vitro' binding of propofol to serum lipoproteins in thyroid dysfunction. Eur J Clin Pharmacol 2002, 58:615-619.
15. de la Fuente L, Lukas JC, Jauregizar N, Vazquez JA, Calvo R, Suarez E: Prediction of unbound propofol concentrations in a diabetic population. Ther Drug Monit 2002, 24:689-695.
16. Costela JL, Jimenez R, Calvo R, Suarez E, Carlos R: Serum protein binding of propofol in patients with renal failure or hepatic cirrhosis. Acta Anaesthesiol Scand 1996, 40:741-745.
17. Altmayer P, Buch U, Buch HP: Propofol binding to human blood proteins. Arzneimittelforschung 1995, 45:1053-1056.
18. Servin F, Desmonts JM, Haberer JP, Cockshott ID, Plummer GF, Farinotti R: Pharmacokinetics and protein binding of propofol in patients with cirrhosis. Anesthesiology 1988, 69:887-891.
19. Mazoit JX, Samil K: Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics. Br J Clin Pharmacol 1999, 47:35-42.
20. Schnider TW, Minto CF, Gambus PL, Andresen C, Goodale DB, Shafer SL, Youngs EJ: The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology 1998, 88:1170-1182.
21. Gallagher D, Visser M, Sepulveda D, Pierson RN, Harris T, Heymsfield SB: How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol 1996, 143:228-239.
22. Gallagher D, Heymsfield SB, Heo M, Jebb SA, Murgatroyd PR, Sakamoto Y: Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr 2000, 72:694-701.
23. Claeys MA, Gepts E, Camu F: Haemodynamic changes during anaesthesia induced and maintained with propofol. Br J Anaesth 1988, 60:3-9.
24. Price ML, Millar B, Grounds M, Cashman J: Changes in cardiac index and estimated systemic vascular resistance during induction of anaesthesia with thiopentone, methohexitone, propofol and etomidate. Br J Anaesth 1992, 69:172-176.
25. Coates DP, Prys-Roberts C, Spelina KR, Monk CR, Norley I: Propofol ('Diprivan') by intravenous infusion with nitrous oxide: dose requirements and haemodynamic effects. Postgrad Med J 1985, 61 Suppl 3:76-79.
26. Grounds RM, Twigley AJ, Carli F, Whitwam JG, Morgan M: The haemodynamic effects of intravenous induction. Comparison of the effects of thiopentone and propofol. Anaesthesia 1985, 40:735-740.
27. Tonner PH, Poppers DM, Miller KW: The general anesthetic potency of propofol and its dependence on hydrostatic pressure. Anesthesiology 1992, 77:926-931.
28. Hansch C, Leo A, Hoekman D: Exploring QSAR. Hydrophobic, Electronic and Steric Constants. Washington, DC, American Chemical Society; 1995.
29. Fan SZ, Yu HY, Chen YL, Liu CC: Propofol concentration monitoring in plasma or whole blood by gas chromatography and high-performance liquid chromatography. Anesth Analg 1995, 81:175-178.
30. Coetzee JF, Glen JB, Wium CA, Boshoff L: Pharmacokinetic model selection for target controlled infusions of propofol. Assessment of three parameter sets. Anesthesiology 1995, 82:1328-1345.
31. Ledwozyw A, Michalak J, Stepien A, Kadziolka A, The relationship between plasma triglycerides, cholesterol, total lipids and lipid peroxidation products during human atherosclerosis. Clin Chim Acta 1986, 155:275-283.
32. Oliver RE, Jones AF, Rowland M: A whole-body physiologically based pharmacokinetic model incorporating dispersion concepts: short and long time characteristics. J Pharmacokinet Biopharm 2001, 28:27-55.
33. Roberts MS, Donaldson JD, Rowland M: Models of hepatic elimination: comparison of stochastic models to describe residence time distributions and to predict the influence of drug distribution, enzyme heterogeneity, and systemic recycling on hepatic elimination. J Pharmacokinet Biopharm 1988, 16:41-83.
34. Ludbrook GL, Upton RN, Grant C, Martinez A: Prolonged dysequillibrium between blood and brain concentrations of propofol during infusions in sheep. Acta Anaesthesiol Scand 1999, 43:206-211.
35. Zheng D, Upton RN, Martinez A: Skeletal muscle kinetics of propofol in anaesthetized sheep: effect of altered muscle blood flow. Xenobiotica 2000, 30:1079-1090.
36. Gray PA, Park GR, Cockshott ID, Douglas EJ, Shuker B, Simons PJ: Propofol metabolism in man during the anhepatic and reperfusion phases of liver transplantation. Xenobiotica 1992, 22:105-114.
37. He YL, Ueyama H, Tashiro C, Mashimo T, Yoshiya I: Pulmonary disposition of propofol in surgical patients. Anesthesiology 2000, 93:986-991.
38. Dawidowicz AL, Fornal E, Mardarowicz M, Fijalkowska A: The role of human lungs in the biotransformation of propofol. Anesthesiology 2000, 93:992-997.
39. Mapleson WW: Circulation-time models of the uptake of inhaled anaesthetics and data for quantifying them. Br J Anaesth 1973, 45:319-334.
40. Servin F, Farinotti R, Haberer JP, Desmonts JM: Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. Anesthesiology 1993, 78:657-665.
41. Rhode BM, Gimmon Z, Shizgal HM: The determination of body fat. J Parenter Enteral Nutr 1987, 11:7S.
42. Virtanen KA, Lonnroth P, Parkkola R, Peltoniemi P, Asola M, Viljanen T. Tolvanen T, Knuuti J, Ronnemaa T, Huupponen R, Nuutila P: Glucose uptake and perfusion in subcutaneous and visceral adipose tissue during insulin stimulation in nonobese and obese humans. J Gin Endocrinol Metab 2002, 87:3902-3910.
43. Alexander JK, Dennis EW, Smith WG, Amad KH, Duncan WC, Austin RC: Blood volume, cardiac output and distribution of systemic blood flow in extreme obesity. Cardiovas Res Cent Bull 1963, 1:39-44.
44. Zauner CW, Arborelius MJ, Swenson EW, Sundstrom, Lindell SE, Fried M: Arterial-venous differences across the lungs in plasma triglyceride concentration. Respiration 1977, 34:2-8.
45. Zwetsch B, Bernath M, Decosterd L, Chassot PG. Ravussin P, Gardaz JP: First pass uptake of propofol in the human lung. Anesthesiology 1996, 85:A329.
46. Gigon VJP, Enderlin F, Scheidegger S: Uber das Schicksal infundieter Fettemulsionen in der menschlichen Lunge. Schweiz med Wschr 1966, 96:71-75.
47. Jonsson F, Johanson G: Physiologically Based Modeling of the Inhalation Kinetics of Styrene in Humans Using a Bayesian Population Approach. Taxicol Appl Pharmacol 2002, 179:35-49.
48. Campbell GA, Morgan DJ, Kumar K, Crankshaw DP: Extended blood collection period required to define distribution and elimination kinetics of propofol. Br J Clin Pharmacol 1988, 26:187-190.
49. Morgan DJ, Campbell GA, Crankshaw DP: Pharmacokinetics of propofol when given by intravenous infusion. Br J Clin Pharmacol 1990, 30:144-148.
50. Albanese J, Martin C, Lacarelle B, Saux P, Durand A, Gouin F: Pharmacokinetics of long-term propofol infusion used for sedation in ICU patients. Anesthesiology 1990, 73:214-217.
51. Andersen ME: Toxicokinetic modeling and its applications in chemical risk assessment. Toxicol Lett 2003, 138:9-27.